Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | PARG | Q86W56 | 1/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | EDNRB | P24530 | 2/20 | 0.48 |
| ▸ | EDNRA | P25101 | 2/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | DUT | P33316 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14677369 | 0.82 | ATM (0.54) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL1348605 | 0.82 | ATM (0.54) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL1347948 | 0.82 | ATM (0.50) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL10016535 | 0.81 | SMN1; SMN2 (1.00) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL23345426 | 0.80 | KMT2A (0.77) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL12093538 | 0.80 | KMT2A (0.71) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL7145890 | 0.80 | LMNA (0.77) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL25382319 | 0.80 | KDM4E (0.45) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL264637 | 0.79 | TNNI3K (0.60) | SMN1; SMN2LMNAHSD17B2ATMEDNRB | |
| SCHEMBL31689440 | 0.79 | TNNI3K (0.60) | SMN1; SMN2LMNAHSD17B2ATMEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | claimed |
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. | 2025-06-12 | — | — | US | disclosed |
| US-20250171469-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-05-29 | — | — | US | disclosed |
| CN-120040345-A | KIF18A inhibitory activity small molecule compound, and pharmaceutical composition and application thereof | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 2025-05-27 | — | — | CN | disclosed |
| EP-4486348-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-118804751-A | New compounds and treatment of renal cell carcinoma | 巴什生物技术公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024179699-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240293406-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | IMPACT BIOMEDICINES INC (US) | 2024-09-05 | — | — | US | disclosed |
| CN-115745896-B | JAK2 kinase selective inhibitor and preparation method and application thereof | 合肥医工医药股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-7238808-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-09-28 | — | — | US | disclosed |
| WO-2006099972-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | PHARMACYCLICS LLC | 2006-09-14 | — | — | US | disclosed |
| EP-1569912-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004062661-A1 | 2-‘5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL!- CARBOXYLIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004050637-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-1189888-A1 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS $i(PDE 4) INHIBITORS | Merck Frosst Canada & Co. (CA) | 2002-03-27 | — | — | EP | disclosed |
| US-6316472-B1 | Heterosubstituted pyridine derivatives as PDE 4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2001-11-13 | — | — | US | disclosed |
| WO-2000069824-A1 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | NAT1, TPMT, ACAT1 | MAPT 181/4885SMN1; SMN2 831/4885KDM4E 1335/4885 |
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | F7, F9, F5 | MAPT 4632/4885SMN1; SMN2 2664/4885KDM4E 173/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | MAPT 3127/4885SMN1; SMN2 4746/4885KDM4E 1689/4885 |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | RCC2, GLS, VHL | MAPT 4564/4885SMN1; SMN2 4206/4885KDM4E 2900/4885 |
| US-20240293406-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | JAK2, NPM1, MCL1 | MAPT 3987/4885SMN1; SMN2 598/4885KDM4E 460/4885 |
| US-20250171469-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | MAPT 4877/4885SMN1; SMN2 4797/4885KDM4E 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.